Novartis' Exelon Patent Is Invalid, UK Appeals Court Says

Law360, New York (December 12, 2012, 4:56 PM EST) -- A U.K. appeals court on Wednesday affirmed a lower court's ruling invalidating a Novartis AG patent covering the company's Alzheimer's drug Exelon in a lawsuit brought by a subsidiary of generic-drug maker Mylan Pharmaceuticals Inc.

A three-judge panel of the England and Wales Court of Appeal said Justice Christopher Floyd didn't err when he determined last year that Novartis' U.K. Patent Number 2,203,040 was made obvious by a series of publications by a team of scientists at Hebrew University of Jerusalem discussing the use of certain...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.